Home
Jemincare

Jemincare Market Share Analysis for June 2026

济民可信集团

Industry: N/A

Domainjemincare.com

Year Founded1999

Employees> 10001

Annual Revenue$2M - $5M

Jemincare

Jemincare (including company regionals)

jemincare.com

See more website traffic and engagement information

Jemincare Revenue up to June 2026 is 2M - 5M

revenue generated by Jemincare top domains

Jemincare top domains revenue over 3 years

Revenue for Jemincare top domains

jemincare.com2M - 5M

See more with Sales Intelligence

Total visits to Jemincare's top domains

Understand Jemincare market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

jemincare.com13.3K

See more with Sales Intelligence

Avg. visit duration in Jemincare's top domains

Analyze Jemincare engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

jemincare.com00:05:16

See more with Sales Intelligence

Avg. pageviews on Jemincare's top domains

See how Jemincare keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

jemincare.com7.28

See more with Sales Intelligence

Jemincare top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Jemincare

These are the website technologies, by industry, used by Jemincare top domains

Advertising (4)

Google Adsense

Conversion & Analytics (2)

CNZZ

Email Services (1)

QQ Mail

Mobile (1)

Meta Viewport

More Technologies

1

See all

News & Signals from Jemincare

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsJemincare receives financing of $35M.- Jemincare receives $35 million upfront payment, up to $672.5 million in milestone payments and high single-digit to low-double digit royalties on future sales -

NewsJemincare partnered with Roche on Aug 18th '22.Jemincare, a leading pharmaceutical company from China, has entered into an exclusive worldwide license agreement with Roche and Genentech, a member of the Roche Group, for the development and commercialization of its androgen receptor degrader, JMKX002992.

NewsGenentech partnered with Jemincare on Aug 18th '22.Roche subsidiary Genentech has inked a licensing deal with China-based Jemincare, gaining worldwide rights to develop and commercialize the company’s investigational androgen receptor degrader JMKX002992.